Cell Reports, Volume *28*

Supplemental Information

A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy

Ahmed O. Hassan, Igor P. Dmitriev, Elena A. Kashentseva, Haiyan Zhao, Douglas E. Brough, Daved H. Fremont, David T. Curiel, and Michael S. Diamond

Table S1. Evaluation of ZIKV vaccine platforms in mice, Related to all Figures

Vaccine platform	Vaccine Efficacy in mice				Reference
	# Doses	Neutralization titer	Protection against ZIKV challenge	Protection against *in utero* transmission	
Gorilla adenovirus encoding prM-E (GAd-Zvp)	1 or 2	FRNT EC_{50} 1,796 ± 919	Yes (No viremia or lethality)	Yes	This study
Ad26.ZIKV.M-Env	1	FRNT EC_{50} ~ 1,000	Yes (No viremia)	N.D.*	(Cox et al., 2018)
Chimpanzee adenovirus type 7 (AdC7-M/E)	1	MN_{50} ~1,000	Yes (No viremia or lethality)	N.D.	(Xu et al., 2018)
mRNA encoding prM-E	2	FRNT EC_{50} 10,000	Yes (No lethality)	Yes	(Richner et al., 2017a, 2017b)
DNA encoding prM-E	1	MN_{50} 22	Yes (No viremia)	N.D.	(Larocca et al., 2016)
DNA encoding E	1	NN_{50} <10	No (viremia detected)	N.D.	(Larocca et al., 2016)
Measles-vectored prM-Zika-sE	2	$PRNT_{50}$ 40 - 1,280	Yes (Viremia and organ viral loads reduced)	Yes **	(Nürnberger et al., 2018)
ZIKV-3′UTR-Δ10-LAV (live attenuated)	1	FRNT EC_{50} 18,900 ± 5,900	Yes (No lethality)	Yes	(Shan et al., 2017a, 2017b)
DNA encoding prM-E	1	$PRNT_{50}$ 456 ± 5	Yes (No lethality)	N.D.	(Muthumani et al., 2016)

DNA encoding prM-E	1	RVP ~1000-100000	ND	N.D.	(Dowd et al., 2016)
Purified inactivated virus	1	MN_{50} 15	Yes (No viremia)	N.D.	(Larocca et al., 2016)
hAd2-vecored prM-E, prM-E-NS1	2	MN_{50} ~1,000	Yes***	N.D.	(Liu et al., 2018)

*N.D. = not determined; FRNT, focus reduction neutralization test; PRNT, plaque reduction neutralization test; MN, microneutralization test; RVP, reporter virus particles.

** Reduced viremia and viral loads in fetuses and maternal tissues

*** Challenge in pups born to immunized dams showed reduced viral loads in brain and testis